


For Research Use Only. NOT for Use in Diagnostic Procedures.

# Sample Preparation Method for Determination of GS-441524 (Remdesivir Metabolite) in Plasma Using ISOLUTE® ENV+ SPE Columns



**Figure 1.** Structural Formula for GS-441524.

## Introduction

GS-441524 (Figure 1) is the main plasma metabolite of the antiviral drug remdesivir. Remdesivir is a nucleoside analog antiviral drug developed by Gilead Sciences for the treatment of Ebola, and both have been found to exhibit antiviral activity against several coronaviruses, including SARS-CoV-2 (COVID-19). GS-441524 is also a promising and inexpensive drug candidate in the treatment of COVID-19 and future emerging coronaviruses. Therapeutic Drug Monitoring (TDM), which measures blood levels of the antibacterial drugs and helps designs dosages for individual patient administration, is critical for effective and safe use of the drugs.

In this application note, ISOLUTE® ENV+ based on a hydroxylated polystyrene divinylbenzene copolymer (Figure 2) was used as a sample preparation column to clean up samples prior to LC-MS/MS analysis. It is suitable for retention of highly polar compounds that are typically not retained by silica-based C18 columns. In this application, GS-441524 could be extracted from plasma samples with high recovery.

## Analytes

GS-441524 (Remdesivir metabolite, CAS: 1191237-69-0)  
Doripenem (Doripenem, CAS: 148016-81-3) used as an Internal Standard (IS).

## Sample Preparation Procedure Format

### Format

ISOLUTE® ENV+ 50 mg/ 1 mL columns,  
(p/n: 915-0005-A)

### Sample Pre-treatment

To 200 µL of plasma, add doripenem as an internal standard at a concentration of 0.1 µg/mL. To this, add 200 µL of 10 mmol/L ammonium formate solution containing 0.1% formic acid and vortex mix for 30 seconds.

### Conditioning

Condition the column with methanol (1 mL).

### Equilibration

Pass through 1 mL of 10 mmol/L ammonium formate solution containing 0.1% formic acid.

### Sample Loading

Load 400 µL of the pre-treated sample.

### Wash

Elute interferences with 1 mL of a 10 mmol/L ammonium formate solution containing 0.1% formic acid.

### Elution

First, elute with 0.4 mL of water:methanol = 8:2 (v/v)


Next, elute with 0.4 mL of methanol.

Mix the two eluates to obtain sample for LC/MS/MS.

### Dilution

Depending on the range of calibration concentration in LC/MS/MS to be used, dilute the sample solution further\*.

\* In this application note, samples were diluted 2.5-fold using purified water.



**Figure 2.** Schematic Representation of ISOLUTE® ENV+.

## UHPLC Conditions

### Instrument

Shimadzu Nexera LC-30AD

### Column

Waters ACQUITY UPLC® BEH C18 1.7  $\mu$ m (2.1 mm  $\times$  50 mm column)

### Mobile Phase

A: 10 mmol/L ammonium formate solution containing 0.1% formic acid

B: Methanol

### Flow Rate

0.4 mL/min.

### Gradient Conditions

Time/% of B: 0/5  $\rightarrow$  1/5  $\rightarrow$  3.5/90  $\rightarrow$  4/90  $\rightarrow$  4.1/5  $\rightarrow$  5/5

### Column Temperature

50 °C

### Injection volume

1  $\mu$ L

## Mass Spectrometry Conditions

### Instrument

Shimadzu LCMS-8060

### Ionization Mode

ESI positive

### Nebulizer Gas Flow Rate

2.80 L/min.

### Drying Gas Flow Rate

10.00 L/min.

### Heating Gas Flow Rate

10.00 L/min.

### Interface Temperature

350 °C

### DL Temperature

200 °C

### Heat Block Temperature

350 °C

### CID Gas

270 kPa

## SRM Transitions

### GS-441524:

$m/z$  292.20  $\rightarrow$  202.20, Rt 1.92 min,  
Collision Energy; -10

### Doripenem:

$m/z$  420.90  $\rightarrow$  274.00, Rt 1.55 min, Collision Energy; -18




Figure 3. SRM Chromatograms of GS-441524 (top) and Doripenem (bottom).

## Results

Figure 3 shows the SRM (Selected Reaction Monitoring) chromatograms of LC-MS/MS analyses of GS-441524 and doripenem (IS). The calibration curve generated is shown in Figure 4. The required blood concentration range for TDM (Therapeutic Drug Monitoring) of GS-441524 is 10 to 1000 ng/mL. In this method, the concentration of GS-441524 was measured at 10-fold dilution from 1 to 100 ng/mL. As a result, a wide dynamic range and good linearity with a multiple correlation coefficient ( $r^2$ ) of 0.999 or higher was obtained.




Figure 4. Calibration Curve for GS-441524 (1.0 ~ 100 ng/mL).

## Confirmation of Analyte Recovery and Matrix Factors


Sample pre-treatment is very important in samples of biological origin. ISOLUTE® ENV+ solid phase extraction columns were used to eliminate the effects of matrix components like protein, phospholipids and salts, and to allow for improved quantitative analyses. The sample used was control plasma with 10 ng/mL GS-441524. The SRM chromatogram obtained by LC/MS/MS measurement after pretreatment is shown in Figure 5). No interference by contaminants was observed.

Next, we evaluated matrix effects using ISOLUTE® ENV+ for cleanup. Three samples of plasma containing 10, 100, and 1000 ng/mL of GS-441524 were prepared using ISOLUTE® ENV+ columns. The recovery rates and matrix factors are shown in Table 1. The recoveries were calculated by comparing the peak area values in plasma samples spiked with GS-441524 before extraction (A) and the peak area value of plasma samples spiked with GS-441524 after extraction (B). Matrix factors were calculated by comparing the peak area values (B) and the standard solution (S). As a result, a high recovery rate of 86.7% to 98.9% was obtained, and the matrix factor was sufficiently small, ranging from 0.5% to 9.3%, confirming that pretreatment with ISOLUTE® ENV+ can efficiently remove matrix effects.

**Table 1.** Recovery Rate and Matrix Factors (n=2) in the Spike Recovery Test.

Blood Concentrations (ng/mL)	Recovery Rate (%)	Matrix Factor (%)
10	98.9	9.3
100	98.6	0.5
1000	86.7	5.0

\* Recovery rate =  $[A]/[B] \times 100$ ; Matrix Factor =  $1 - [B]/[S] \times 100$ .



**Figure 5.** SRM Chromatograms after SPE with ISOLUTE® ENV+ for GS-441524 10 ng/mL in plasma.

## Ordering Information

Part Number	Description	Quantity
<b>915-0005-A</b>	ISOLUTE® ENV+ 50 mg/1 mL	100/pk
<b>PPM-48</b>	Biotage® PRESSURE+ 48 Positive Pressure Manifold	1
<b>121-2016</b>	Biotage® VacMaster™ 20 Sample Processing Manifold	1

## Acknowledgement

This application note was prepared in collaboration with the Pharmaceutical Department of Gunma University Hospital, Japan.

### EUROPE

Main Office: +46 18 565900  
Toll Free: +800 18 565710  
Fax: +46 18 591922  
Order Tel: +46 18 565710  
Order Fax: +46 18 565705  
order@biotage.com  
Support Tel: +46 18 56 59 11  
Support Fax: +46 18 56 57 11  
eu-1-pointsupport@biotage.com

### NORTH & LATIN AMERICA

Main Office: +1 704 654 4900  
Toll Free: +1 800 446 4752  
Fax: +1 704 654 4917  
Order Tel: +1 704 654 4900  
Order Fax: +1 434 296 8217  
ordermailbox@biotage.com  
Support Tel: +1 800 446 4752  
Outside US: +1 704 654 4900  
us-1-pointsupport@biotage.com

### JAPAN

Tel: +81 3 5627 3123  
Fax: +81 3 5627 3121  
jp\_order@biotage.com  
jp-1-pointsupport@biotage.com

### CHINA

Tel: +86 21 68162810  
Fax: +86 21 68162829  
cn\_order@biotage.com  
cn-1-pointsupport@biotage.com

### KOREA

Tel: +82 31 706 8500  
Fax: +82 31 706 8510  
korea\_info@biotage.com  
kr-1-pointsupport@biotage.com

### INDIA

Tel: +91 11 45653772  
india@biotage.com

Distributors in other regions are listed on [www.biotage.com](http://www.biotage.com)

Literature Number: AN959.V.1

© 2021 Biotage. All rights reserved. No material may be reproduced or published without the written permission of Biotage. Information in this document is subject to change without notice and does not represent any commitment from Biotage. E&OE. A list of all trademarks owned by Biotage AB is available at [www.biotage.com/legal](http://www.biotage.com/legal). Other product and company names mentioned herein may be trademarks or registered trademarks and/or service marks of their respective owners, and are used only for explanation and to the owners' benefit, without intent to infringe. **FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.**